company background image
PROC

Procaps Group NasdaqGM:PROC Stock Report

Last Price

US$4.31

Market Cap

US$486.3m

7D

-4.2%

1Y

-53.8%

Updated

29 Jan, 2023

Data

Company Financials +

PROC Stock Overview

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide.

PROC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance2/6
Financial Health0/6
Dividends0/6

My Notes

New

Notes are coming soon

Procaps Group S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Procaps Group
Historical stock prices
Current Share PriceUS$4.31
52 Week HighUS$10.20
52 Week LowUS$4.10
Beta0.091
1 Month Change-17.90%
3 Month Change-41.52%
1 Year Change-53.80%
3 Year Change-56.64%
5 Year Changen/a
Change since IPO-56.20%

Recent News & Updates

Recent updates

Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)

Jan 10
Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)

Shareholder Returns

PROCUS PharmaceuticalsUS Market
7D-4.2%-1.4%2.8%
1Y-53.8%4.5%-9.2%

Return vs Industry: PROC underperformed the US Pharmaceuticals industry which returned 4.5% over the past year.

Return vs Market: PROC underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is PROC's price volatile compared to industry and market?
PROC volatility
PROC Average Weekly Movement8.4%
Pharmaceuticals Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: PROC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: PROC's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19775,300Ruben Minskihttps://www.procapsgroup.com

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.

Procaps Group S.A. Fundamentals Summary

How do Procaps Group's earnings and revenue compare to its market cap?
PROC fundamental statistics
Market CapUS$486.27m
Earnings (TTM)US$60.11m
Revenue (TTM)US$434.99m

8.1x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PROC income statement (TTM)
RevenueUS$434.99m
Cost of RevenueUS$172.02m
Gross ProfitUS$262.97m
Other ExpensesUS$202.87m
EarningsUS$60.11m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.53
Gross Margin60.46%
Net Profit Margin13.82%
Debt/Equity Ratio-2,085.0%

How did PROC perform over the long term?

See historical performance and comparison